trending Market Intelligence /marketintelligence/en/news-insights/trending/DuxUmoVENpcnT8vQsLmbxw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sorrento's partner seeks approval of biosimilar to J&J's Remicade in China

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sorrento's partner seeks approval of biosimilar to J&J's Remicade in China

Sorrento Therapeutics Inc.'s partner Mabpharm Ltd. filed an application in China seeking approval for a biosimilar of Johnson & Johnson's blockbuster medicine Remicade.

A biosimilar is a biological product that is similar to a reference drug in terms of safety and efficacy.

China-based Mabpharm, which went public on the Hong Kong Stock Exchange in May 2019, had submitted a new drug application to China's National Medical Products Administration for the biosimilar antibody-based on Remicade, or infliximab.

Remicade is an injectable drug that is used to treat rheumatoid arthritis, Crohn's disease and psoriatic arthritis, among other things. The J&J medicine generated worldwide sales of $3.35 billion for the nine months ended Sept. 30, 2019, down from $4.09 billion in the same period a year ago.

Sorrento said in a Jan. 6 press release that it is planning to file all the required documents for a biologics license application for the biosimilar drug candidate in the U.S. by the end of 2020.

San Diego-based Sorrento noted that it owns the global rights to Mabpharm's infliximab biosimilar antibody outside of China under a licensing agreement with the Chinese company.